Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma

Journal of Surgical Oncology

Volumn 109, Issue 8, 2014, Pages 780-785

  Coventry, Brendon J ^a   Kroon, Hidde M ^a   Giles, Mitchell H ^a   Henderson, Michael ^b   Speakman, David ^b   Wall, Mark ^b   Barbour, Andrew ^c   Serpell, Jonathan ^d   Paddle, Paul ^d   Coventry, Alexander G J ^a   Sullivan, Thomas ^a   Smithers, B Mark ^c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ALFRED HOSPITAL   (Australia)

Author keywords

chemotherapy; isolated limb infusion; metastatic melanoma

Indexed keywords

DACTINOMYCIN; MELPHALAN;

ADULT; AGED; AMPUTATION; ARTERY THROMBOSIS; ARTICLE; AUSTRALIA; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPARTMENT SYNDROME; EDEMA; EPIDERMOLYSIS; ERYTHEMA; FALSE ANEURYSM; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; ISOLATED LIMB INFUSION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; TERTIARY CARE CENTER; TISSUE INJURY; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; VERY ELDERLY; WORLD HEALTH ORGANIZATION;

CHEMOTHERAPY; ISOLATED LIMB INFUSION; METASTATIC MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALIA; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 84900563190     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23590     Document Type: Article

References (39)

1. Australian Institute of Health and Welfare. Australasian Association of Cancer Registries 2012. Cancer in Australia: An overview, 2012. Australian Cancer Incidence and Mortality workbooks-Melanoma. Cancer series no. 74. Cat. no. CAN 70. Canberra: AIHW; 2012.
2. Francken AB, Accortt NA, Shaw HM, et al.: Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol 2008; 15: 1476-1484.
3. Testori A, Faries MB, Thompson JF, et al.: Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol 2011; 104: 391-396.
4. Creech O Jr, Krementz ET, Ryan RF, et al.: Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148: 616-632.
5. Moreno-Ramirez D, de la Cruz-Merino L, Ferrandiz L, et al.: Isolated limb perfusion for malignant melanoma: Systematic review on effectiveness and safety. Oncologist 2010; 15: 416-427.
6. Thompson JF, Waugh RC, Saw RPM, et al.: Isolated limb infusion with melphalan for recurrent limb melanoma: A simple alternative to isolated limb perfusion. Reg Cancer Treat 1994; 7: 188-192.
7. Thompson JF, Kam PC, Waugh RC, et al.: Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. Semin Surg Oncol 1998; 14: 238-247.
8. Kroon HM, Thompson JF:, Isolated limb infusion: A review. J Surg Oncol 2009; 100: 169-177.
9. Testori A, Verhoef C, Kroon HM, et al.: Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion. J Surg Oncol 2011; 104: 397-404.
10. Kroon HM, Moncrieff M, Kam PC, et al.: Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 2008; 15: 3003-3013.
11. Barbour AP, Thomas J, Suffolk J, et al.: Isolated limb infusion for malignant melanoma: predictors of response and outcome. Ann Surg Oncol 2009; 16: 3463-3472.
12. Beasley GM, Petersen RP, Yoo YS:, Isolated limb infusion for intransit malignant melanoma of the extremity: A well tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008; 15: 2195-2205.
13. Beasley GM, Caudle A, Petersen RP, et al.: A multi-institutional experience of isolated limb infusion: Defining response and toxicity in the US. J Am Coll Surg 2009; 208: 706-715.
14. Balch CM, Gershenwald JE, Soong SJ, et al.: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
15. Thompson JF, Kam PCA, de Wilt JHW, et al.: Isolated limb infusion for melanoma. In:, Thompson JF, Morton DL, Kroon BBR, editors. Textbook of melanoma. London: Martin Dunitz; 2004 pp. 429-437.
16. Giles MH, Coventry BJ,. Isolated limb infusion chemotherapy for melanoma: An overview of early experience at the Adelaide Melanoma Unit. Cancer Manag Res 2013; 5: 243-249.
17. Sanki A, Kam PCA, Thompson JF:, Long-term results of hyperthermic isolated limb perfusion for melanoma. Ann Surg 2007; 4: 591-596
18. Lindner P, Doubrovsky A, Kam PC, et al.: Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002; 9: 127-136.
19. Wieberdink J, Benckhuysen C, Braat RP, et al.: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905-910.
20. Lai DTM, Ingvar C, Thompson JF:, The value of monitoring serum creatine phosphokinase values following hyperthermic isolated limb perfusion for melanoma. Reg Cancer Treat 1993; 6: 36-39.
21. Kroon HM, Moncrieff M, Kam PC, et al.: Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Ann Surg Oncol 2009; 16: 1184-1192.
22. World Health Organization. WHO handbook for reporting results of cancer treatments (WHO offset publication no. 48). Geneva: World Health Organization; 1979.
23. Kaplan L, Meier P:, Nonparametric estimation from incomplete observations. J Am Stat Assoc 1985; 53: 457-481.
24. Cox DR:, Regression models and life table. J Stat Soc 1972; 34: 187-220.
25. Brady MS, Brown K, Patel A, et al.: A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 2006; 13: 1123-1129.
26. Huismans AM, Kroon HM, Kam PC, et al.: Does increased experience with isolated limb infusion for advanced limb melanoma influence outcome? A comparison of two treatment periods at a single institution. Ann Surg Oncol 2011; 18: 1877-1883.
27. Vrouenraets BC, Nieweg OE, Kroon BB:, Thirty-five years of isolated limb perfusion for melanoma: Indications and results. Br J Surg 1996; 83: 1319-1328.
28. Siemann DW, Chapman M, Beikirch A:, Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys 1991; 20: 287-289.
29. Sanki A, Kroon HM, Kam PCA, et al.: Isolated limb perfusion and isolated limb infusion for malignant lesions of the extremities. Curr Probl Surg 2011; 48: 371-430.
30. Beasley GM, Sharma K, Wong J, et al.: A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion. Cancer 2012; 118: 6136-6143.
31. Kroon HM, Lin DY, Kam PC, et al.: Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma. Ann Surg 2009; 249: 1008-1013.
32. Santillan AA, Delman KA, Beasley GM, et al.: Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: A multi-institutional analysis. Ann Surg Oncol 2009; 16: 2570-2578.
33. Klaase JM, Kroon BB, Beijnen JH, et al.: Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer 1994; 70: 151-153.
34. Klaase JM, Kroon BB, van Geel BN, et al.: Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg 1994; 167: 618-620.
35. Vrouenraets BC, Klaase JM, Kroon BB, et al.: Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg 1995; 130: 43-47.
36. Huismans AM, Kroon HM, Haydu LE, et al.: Is melphalan dose adjustment according to ideal body weight useful in isolated limb infusion for melanoma ? Ann Surg Oncol 2012; 19: 3050-3056.
37. Vrouenraets BC, Klaase JM, Nieweg OE, et al.: Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol 1998; 14: 224-231.
38. Koops HS, Vaglini M, Suciu S, et al.: Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial. J Clin Oncol 1998; 16: 2906-2912.
39. Lasithiotakis K, Leiter U, Meier F, et al.: Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer 2008; 112: 1795-1804.